Literature DB >> 24336173

Sustained correction of motoneuron histopathology following intramuscular delivery of AAV in pompe mice.

Mai K Elmallah1, Darin J Falk2, Sushrusha Nayak2, Roland A Federico3, Milapjit S Sandhu3, Amy Poirier4, Barry J Byrne2, David D Fuller5.   

Abstract

Pompe disease is an autosomal recessive disorder caused by mutations in the acid-α glucosidase (GAA) gene. Lingual dysfunction is prominent but does not respond to conventional enzyme replacement therapy (ERT). Using Pompe (Gaa(-/-)) mice, we tested the hypothesis that intralingual delivery of viral vectors encoding GAA results in GAA expression and glycogen clearance in both tongue myofibers and hypoglossal (XII) motoneurons. An intralingual injection of an adeno-associated virus (AAV) vector encoding GAA (serotypes 1 or 9; 1 × 10(11) vector genomes, CMV promoter) was performed in 2-month-old Gaa(-/-) mice, and tissues were harvested 4 months later. Both serotypes robustly transduced tongue myofibers with histological confirmation of GAA expression (immunochemistry) and glycogen clearance (Period acid-Schiff stain). Both vectors also led to medullary transgene expression. GAA-positive motoneurons did not show the histopathologic features which are typical in Pompe disease and animal models. Intralingual injection with the AAV9 vector resulted in approximately threefold more GAA-positive XII motoneurons (P < 0.02 versus AAV1); the AAV9 group also gained more body weight over the course of the study (P < 0.05 versus AAV1 and sham). We conclude that intralingual injection of AAV1 or AAV9 drives persistent GAA expression in tongue myofibers and motoneurons, but AAV9 may more effectively target motoneurons.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24336173      PMCID: PMC3982493          DOI: 10.1038/mt.2013.282

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  46 in total

1.  Interpreting Penh in mice.

Authors:  Wayne Mitzner; Clarke Tankersley
Journal:  J Appl Physiol (1985)       Date:  2003-02

Review 2.  Pathophysiology of neuropathic lysosomal storage disorders.

Authors:  Cinzia Maria Bellettato; Maurizio Scarpa
Journal:  J Inherit Metab Dis       Date:  2010-04-29       Impact factor: 4.982

3.  Sustained production of beta-glucuronidase from localized sites after AAV vector gene transfer results in widespread distribution of enzyme and reversal of lysosomal storage lesions in a large volume of brain in mucopolysaccharidosis VII mice.

Authors:  A F Skorupa; K J Fisher; J M Wilson; M K Parente; J H Wolfe
Journal:  Exp Neurol       Date:  1999-11       Impact factor: 5.330

4.  Physiological correction of Pompe disease by systemic delivery of adeno-associated virus serotype 1 vectors.

Authors:  Cathryn Mah; Christina A Pacak; Kerry O Cresawn; Lara R Deruisseau; Sean Germain; Melissa A Lewis; Denise A Cloutier; David D Fuller; Barry J Byrne
Journal:  Mol Ther       Date:  2007-01-23       Impact factor: 11.454

5.  Treatment of infantile Pompe disease with alglucosidase alpha: the UK experience.

Authors:  Anupam Chakrapani; Ashok Vellodi; Peter Robinson; Simon Jones; J E Wraith
Journal:  J Inherit Metab Dis       Date:  2010-09-24       Impact factor: 4.982

Review 6.  The respiratory neuromuscular system in Pompe disease.

Authors:  David D Fuller; Mai K ElMallah; Barbara K Smith; Manuela Corti; Lee Ann Lawson; Darin J Falk; Barry J Byrne
Journal:  Respir Physiol Neurobiol       Date:  2013-06-21       Impact factor: 1.931

7.  Retrograde gene delivery to hypoglossal motoneurons using adeno-associated virus serotype 9.

Authors:  Mai K ElMallah; Darin J Falk; Michael A Lane; Thomas J Conlon; Kun-Ze Lee; Nadeem I Shafi; Paul J Reier; Barry J Byrne; David D Fuller
Journal:  Hum Gene Ther Methods       Date:  2012-04       Impact factor: 2.396

8.  B-Cell depletion and immunomodulation before initiation of enzyme replacement therapy blocks the immune response to acid alpha-glucosidase in infantile-onset Pompe disease.

Authors:  Melissa E Elder; Sushrusha Nayak; Shelley W Collins; Lee Ann Lawson; Jeffry S Kelley; Roland W Herzog; Renee F Modica; Judy Lew; Robert M Lawrence; Barry J Byrne
Journal:  J Pediatr       Date:  2013-04-16       Impact factor: 4.406

9.  Intramuscular injection of AAV-GDNF results in sustained expression of transgenic GDNF, and its delivery to spinal motoneurons by retrograde transport.

Authors:  Yan-Yan Lu; Li-Jun Wang; Shin-ichi Muramatsu; Kunihiko Ikeguchi; Ken-ichi Fujimoto; Takashi Okada; Hiroaki Mizukami; Takashi Matsushita; Yutaka Hanazono; Akihiro Kume; Toshiharu Nagatsu; Keiya Ozawa; Imaharu Nakano
Journal:  Neurosci Res       Date:  2003-01       Impact factor: 3.304

10.  Hypoglossal neuropathology and respiratory activity in pompe mice.

Authors:  Kun-Ze Lee; Kai Qiu; Milapjit S Sandhu; Mai K Elmallah; Darin J Falk; Michael A Lane; Paul J Reier; Barry J Byrne; David D Fuller
Journal:  Front Physiol       Date:  2011-06-30       Impact factor: 4.566

View more
  41 in total

Review 1.  An emerging phenotype of central nervous system involvement in Pompe disease: from bench to bedside and beyond.

Authors:  Aditi Korlimarla; Jeong-A Lim; Priya S Kishnani; Baodong Sun
Journal:  Ann Transl Med       Date:  2019-07

2.  Stimulation of Respiratory Motor Output and Ventilation in a Murine Model of Pompe Disease by Ampakines.

Authors:  Mai K ElMallah; Silvia Pagliardini; Sara M Turner; Anthony J Cerreta; Darin J Falk; Barry J Byrne; John J Greer; David D Fuller
Journal:  Am J Respir Cell Mol Biol       Date:  2015-09       Impact factor: 6.914

Review 3.  Pompe Disease: From Basic Science to Therapy.

Authors:  Lara Kohler; Rosa Puertollano; Nina Raben
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

4.  Intralingual Administration of AAVrh10-miRSOD1 Improves Respiratory But Not Swallowing Function in a Superoxide Dismutase-1 Mouse Model of Amyotrophic Lateral Sclerosis.

Authors:  Lori A Lind; Ellyn M Andel; Angela L McCall; Justin S Dhindsa; Katherine A Johnson; Olivia E Stricklin; Christian Mueller; Mai K ElMallah; Teresa E Lever; Nicole L Nichols
Journal:  Hum Gene Ther       Date:  2020-07-13       Impact factor: 5.695

5.  The Gene Therapy Resource Program: A Decade of Dedication to Translational Research by the National Heart, Lung, and Blood Institute.

Authors:  Terence R Flotte; Eric Daniels; Janet Benson; Jeneé M Bevett-Rose; Kenneth Cornetta; Margaret Diggins; Julie Johnston; Susan Sepelak; Johannes C M van der Loo; James M Wilson; Cheryl L McDonald
Journal:  Hum Gene Ther Clin Dev       Date:  2017-11-27       Impact factor: 5.032

6.  Correcting Neuromuscular Deficits With Gene Therapy in Pompe Disease.

Authors:  Adrian G Todd; Jessica A McElroy; Robert W Grange; David D Fuller; Glenn A Walter; Barry J Byrne; Darin J Falk
Journal:  Ann Neurol       Date:  2015-06-30       Impact factor: 10.422

7.  Systemic Delivery of AAVB1-GAA Clears Glycogen and Prolongs Survival in a Mouse Model of Pompe Disease.

Authors:  Allison M Keeler; Marina Zieger; Sophia H Todeasa; Angela L McCall; Jennifer C Gifford; Samantha Birsak; Sourav R Choudhury; Barry J Byrne; Miguel Sena-Esteves; Mai K ElMallah
Journal:  Hum Gene Ther       Date:  2018-07-25       Impact factor: 5.695

Review 8.  Combination Therapies for Lysosomal Storage Diseases: A Complex Answer to a Simple Problem.

Authors:  Shannon L Macauley
Journal:  Pediatr Endocrinol Rev       Date:  2016-06

9.  Safety of Intradiaphragmatic Delivery of Adeno-Associated Virus-Mediated Alpha-Glucosidase (rAAV1-CMV-hGAA) Gene Therapy in Children Affected by Pompe Disease.

Authors:  Manuela Corti; Cristina Liberati; Barbara K Smith; Lee Ann Lawson; Ibrahim S Tuna; Thomas J Conlon; Kirsten E Coleman; Saleem Islam; Roland W Herzog; David D Fuller; Shelley W Collins; Barry J Byrne
Journal:  Hum Gene Ther Clin Dev       Date:  2017-12       Impact factor: 5.032

10.  Transcriptome assessment of the Pompe (Gaa-/-) mouse spinal cord indicates widespread neuropathology.

Authors:  S M F Turner; D J Falk; B J Byrne; D D Fuller
Journal:  Physiol Genomics       Date:  2016-09-09       Impact factor: 3.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.